June 28, 2024

Grifols discloses transfers of value made to European healthcare professionals and healthcare organizations in 2023

Download PDF
  • In line with its commitment to transparency, Grifols has disclosed for the ninth consecutive year all payments and other transfers of value related to medicines and medical technology made to healthcare professionals and healthcare organizations in the several European countries listed within the EFPIA’s scope, including Spain.
  • In 2023, Grifols made transfers of value in Europe amounting to Euro 14.5 million. This represents a decrease of 25% compared to 2022. 68.9% of the total were transfers of value related to R&D, amounting to Euro 10.0 million.
  • Transfers of value to healthcare organizations and healthcare professionals amounted to Euro 4.5 million, representing a decrease of 4% compared to the previous year.
  • Transfers of value in Spain decreased by 43% to Euro 7.1 million, although Spain generated 49% of the group’s total transfers in Europe in 2023 and 62% of those related to R&D.
  • In 2023, Grifols made transfers of value to 261 healthcare professionals in Spain that amounted to Euro 297,491 and 64 healthcare organizations, which totaled Euro 597,865.
  • The EFPIA Code of Practice, which promotes transparency in industry interactions with healthcare professionals, healthcare organizations and patient organizations, applies specifically to medicines. Nonetheless Grifols expands its scope to include transfers unrelated to medications, as well as to all the company’s divisions. In addition to Europe, Grifols applies this policy of transparency to the United States in accordance with CMS (Centers for Medicare & Medicaid Services) Open Payments. All related information is public and available on the Grifols corporate website: www.grifols.com

Information Published in Accordance with the EFPIA Code of Practice

Grifols has voluntarily committed to publishing, on its website and on any specific platform required by each country, information on transfers of value to health professionals and healthcare organizations corresponding to each reporting period. The company will keep this information publicly available for three years and conserve it for six years.

Depending on the type of activity, the published information includes: donations and subsidies; corporate contributions for events, such as membership fees for healthcare professionals and sponsorship agreements with healthcare organizations, as well as payments to third parties designated to manage the event on their behalf; fees paid for consulting services and projects; travel and accommodation expenses incurred in relation to any of the aforementioned activities, and payments and other transfers of value related to R&D activities.

Specifically, the code of conduct is applied in the following European countries: Austria, Belgium, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine and the United Kingdom.